Disease, Synthetic Chemistry and Treatment

Enthera Pharmaceuticals Appoints Kazumi Shiosaki to Its Board of Directors and Lisa Olson to Its Scientific Advisory Board to Push Forward Company Growth and Development

The Pharma Data

DECEMBER 2, 2020

Kazumi was also a co-founder and CEO of Mitobridge, a start-up company developing mitochondrial drugs for the treatment of muscle and kidney diseases, until its acquisition by Astellas Pharma in 2018. Kazumi holds a PhD in Synthetic Chemistry from UC Berkeley. 3, 2020 08:00 UTC.

Pharmaceuticals

Pharmaceuticals Synthetic Chemistry RNA Disease

BetterLife Engages Eurofins Discovery for its Next Generation Psychedelics 2-bromo-LSD FDA IND-enabling Pharmacology Studies

The Pharma Data

JANUARY 27, 2021

BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, announces it has entered into an agreement with Eurofins Discovery for TD-0148A’s U.S. VANCOUVER, Jan.

FDA

FDA Synthetic Chemistry Assay Development Treatment

AWS helps Pfizer accelerate drug development and clinical manufacturing

The Pharma Data

DECEMBER 4, 2021

The documents include data related to synthetic chemistry routes, recipes, analytical tests, method development, formulation composition, clinical manufacturing campaigns, batch records, technology transfer, and many other types of work.

Drug Development

Drug Development Small Molecule Synthetic Chemistry Drugs

Drug Discovery Digest

Enthera Pharmaceuticals Appoints Kazumi Shiosaki to Its Board of Directors and Lisa Olson to Its Scientific Advisory Board to Push Forward Company Growth and Development

BetterLife Engages Eurofins Discovery for its Next Generation Psychedelics 2-bromo-LSD FDA IND-enabling Pharmacology Studies

AWS helps Pfizer accelerate drug development and clinical manufacturing

Stay Connected